Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL27521103 | 0.87 | ALDH1A1 (0.41) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL15863806 | 0.81 | L3MBTL1 (0.32) | LMNAMEN1KMT2A | |
| SCHEMBL6259211 | 0.77 | ALDH1A1 (0.40) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL12603635 | 0.75 | RAB9A (0.47) | ALDH1A1LMNATSHRMEN1KMT2A | |
| SCHEMBL1044189 | 0.74 | KMT2A (0.54) | MEN1KMT2AMAPTKDM4ETDP1 | |
| SCHEMBL10611050 | 0.73 | CALM1 (0.44) | ALDH1A1LMNAMEN1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL1875423 | 0.73 | KMT2A (0.53) | MEN1KMT2AMAPTKDM4ETDP1 | |
| Ethylene SCHEMBL28111857 | 0.71 | KMT2A (0.51) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL12562408 | 0.71 | MEN1 (0.41) | LMNATSHRMEN1KMT2AHPGD | |
| SCHEMBL19745843 | 0.70 | KMT2A (0.42) | ALDH1A1LMNAMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195463-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) | 2025-06-19 | — | — | US | claimed |
| EP-4508058-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | Faculdade de Ciencias da Universidade de Lisboa (PT) | 2025-02-19 | — | — | EP | claimed |
| WO-2023199134-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2023-10-19 | — | — | WO | claimed |
| US-20260098081-A1 | METABOLIC SELECTION VIA THE GLYCINE-FORMATE BIOSYNTHESIS PATHWAY | SIGMA ALDRICH CO LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260085327-A1 | METABOLIC SELECTION VIA THE SERINE BIOSYNTHESIS PATHWAY | SIGMA ALDRICH CO LLC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260028611-A1 | METABOLIC SELECTION VIA ASPARAGINE BIOSYNTHESIS PATHWAY | SIGMA ALDRICH CO LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | disclosed |
| US-12435121-B2 | Compositions and methods for stimulating natural killer cells | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4594507-A1 | METABOLIC SELECTION VIA THE GLYCINE-FORMATE BIOSYNTHESIS PATHWAY | Sigma-Aldrich Co. LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250235558-A1 | DEGRON FUSION CONSTRUCTS | VECTORY THERAPEUTICS B.V. (NL) | 2025-07-24 | — | — | US | disclosed |
| US-20250195463-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) | 2025-06-19 | — | — | US | disclosed |
| US-20190249200-A1 | ENGINEERED CAS9 SYSTEMS FOR EUKARYOTIC GENOME MODIFICATION | SIGMA-ALDRICH CO. LLC | 2019-08-15 | — | — | US | disclosed |
| WO-2019027728-A1 | SYNTHETIC GUIDE RNA FOR CRISPR/CAS ACTIVATOR SYSTEMS | SIGMA-ALDRICH CO. LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20190032053-A1 | SYNTHETIC GUIDE RNA FOR CRISPR/CAS ACTIVATOR SYSTEMS | SIGMA-ALDRICH CO. LLC | 2019-01-31 | — | — | US | disclosed |
| US-20190017042-A1 | USING NUCLEOSOME INTERACTING PROTEIN DOMAINS TO ENHANCE TARGETED GENOME MODIFICATION | SIGMA-ALDRICH CO. LLC | 2019-01-17 | — | — | US | disclosed |
| EP-3428274-A1 | USING NUCLEOSOME INTERACTING PROTEIN DOMAINS TO ENHANCE TARGETED GENOME MODIFICATION | Sigma Aldrich Co. LLC (US) | 2019-01-16 | — | — | EP | disclosed |
| US-8575359-B2 | Acid-sensitive linkers for drug delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110053878-A1 | ACID-SENSITIVE LINKERS FOR DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-03-03 | — | — | US | disclosed |
| US-20080031883-A1 | Condition-dependent, multiple target delivery system | NORTHEASTERN UNIVERSITY | 2008-02-07 | — | — | US | disclosed |
| WO-2007114946-A2 | ACID-SENSITIVE LINKERS FOR DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085327-A1 | METABOLIC SELECTION VIA THE SERINE BIOSYNTHESIS PATHWAY | ASNS, PSPH, TYMS | ALDH1A1 3556/4885LMNA 4503/4885TSHR 2196/4885 |
| US-20260028611-A1 | METABOLIC SELECTION VIA ASPARAGINE BIOSYNTHESIS PATHWAY | ASNS, GLUL, NARS1 | ALDH1A1 4098/4885LMNA 2992/4885TSHR 2629/4885 |
| US-20250195463-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | SAMM50, CYP4F2, ABCB1 | ALDH1A1 1096/4885LMNA 4866/4885TSHR 3207/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | ALDH1A1 2270/4885LMNA 514/4885TSHR 4141/4885 |
| US-20260098081-A1 | METABOLIC SELECTION VIA THE GLYCINE-FORMATE BIOSYNTHESIS PATHWAY | ASNS, SHMT1, PSPH | ALDH1A1 1919/4885LMNA 4496/4885TSHR 2921/4885 |
| US-20110053878-A1 | ACID-SENSITIVE LINKERS FOR DRUG DELIVERY | CD44, MSN, ABCC1 | ALDH1A1 491/4885LMNA 709/4885TSHR 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.